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Abstract
Objectives: To develop a valid and reliable quantitative measure of leprosy Type 1 reactions.
Methods: A scale was developed from previous scales which had not been validated. The face and content validity were
assessed following consultation with recognised experts in the field. The construct validity was determined by applying the
scale to patients in Bangladesh and Brazil who had been diagnosed with leprosy Type 1 reaction. An expert categorized
each patient’s reaction as mild or moderate or severe. Another worker applied the scale. This was done independently. In a
subsequent stage of the study the agreement between two observers was assessed.
Results: The scale had good internal consistency demonstrated by a Cronbach’s alpha .0.8. Removal of three items from the
original scale resulted in better discrimination between disease severity categories. Cut off points for Type 1 reaction severities
were determined using Receiver Operating Characteristic curves. A mild Type 1 reaction is characterized using the final scale
by a score of 4 or less. A moderate reaction is a score of between 4.5 and 8.5. A severe reaction is a score of 9 or more.
Conclusions: We have developed a valid and reliable tool for quantifying leprosy Type 1 reaction severity and believe this
will be a useful tool in research of this condition, in observational and intervention studies, and in the comparison of clinical
and laboratory parameters.
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Introduction
Leprosy is a chronic granulomatous disease caused by
Mycobacterium leprae. More than 254 000 new cases were reported
to the World Health Organization in 2007 [1].
The disease predominantly affects the skin and nerves. The
nerve involvement associated with the disease may lead to
permanent deformity and disability. A spectrum of disease
phenotypes is recognised and these are determined by the host
response to the organism [2]. The tuberculoid pole of the
spectrum is characterised by strong host cell mediated immunity
to the organism, whereas patients with lepromatous leprosy have a
predominantly humoral immune response [3]. The borderline
states of the disease are immunologically unstable.
Leprosy may be exacerbated by immunological complications–
Type 1 (reversal) reactions and erythema nodosum leprosum
(Type 2 reactions).
Type 1 reactions occur predominantly in individuals with the
borderline forms of leprosy. They are characterised by inflamma-
tion of the skin, nerves or both. Type 1 reactions may occur
before, during or after the successful completion of multi-drug
therapy. Type 1 reactions affecting the peripheral nerves may
result in decreased sensory and motor function and lead to
disability. 20–30% of individuals diagnosed with leprosy will have
a Type 1 reaction [4,5].
Type 1 reactions are usually treated with oral corticosteroids but
approximately 40% of individuals do not experience complete
recovery of clinically detectable nerve function impairment (NFI)
[6]. Clinical trials with appropriate outcome measures are needed
to determine the most effective treatment regimens [7]. It has
proved difficult to compare the small number of studies because of
the different outcome measures used. There are also difficulties in
comparing the severity of Type 1 reactions between different
cohorts and even between different arms of clinical trials.
A tool which enables clinicians to accurately assess the severity
of leprosy Type 1 reactions would be useful in defining outcomes
for clinical trials. It would facilitate the even distribution of patients
with similar disease severity between the arms of clinical trials. A
measure of reaction severity could also be used in treatment
guidelines to indicate the need for therapy. A quantitative measure
of reaction severity may be a useful prognostic tool.
A scale devised as part of the ILEP Nerve Function Impairment
and Reaction (INFIR) Cohort study examined 21 parameters for
the basis of a severity scale of both Types of reactions and
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was good agreement between items in the scale.
A different scale (with 24 parameters) was used by Marlowe et al
in a different INFIR study of azathioprine and prednisolone in
Type 1 reactions but it was not validated [9]. An ‘‘indice
ne ´vritique’’–a composite scale using various assessments of nerves
including electrophysiological studies–was developed by Naafs and
colleagues but has not been validated [10,11].
Using the INFIR scales as a starting point we decided to develop
and validate a scale for Type 1 reactions and nerve function
impairment in leprosy.
Methods
Expert opinion
A questionnaire was sent to eight leprologists who were not
involved in the development of the current scale. The question-
naire used open questions to ascertain the signs they believed to be
important in Type 1 reaction, which signs indicated a more severe
reaction and how they categorised Type 1 reaction severity.
Scale development
The severity scale for leprosy Type 1 reactions was developed
by modifying the two previous scales used in the INFIR studies.
The scale we developed and tested has 24 parameters grouped into
three parts (see Appendix S1):
Section A contained six parameters which scored between 0 and
3 depending on the assessment of their severity by the examiner
using the scale.
Section B is an assessment of sensory function of each of the
trigeminal, ulnar, median and posterior tibial nerves. Cotton wool
is used to assess the trigeminal nerve. Graded Semmes-Weinstein
monofilaments (SWM) are used for the ulnar, median and
posterior tibial nerves.
The ulnar and median nerves are examined using a 2 and 10g
monofilament at three sites on the palmar aspect of the hand for
each nerve (ulnar and median) and the posterior tibial nerves are
assessed using 10 and 300g at four sites on the sole of the foot
(Fig. 1). A score from 0 to 6 was assigned depending on the ability
of the patient to successfully recognise the weighted monofilaments
and the number of sites in which they were felt. For example, on
the hand if a person could feel the 2g monofilament at the three
sites innervated by the ulnar nerve then a score of zero was
recorded. If the 2g was felt at two sites and the 10g at the third site
a score of one was recorded. If however the 10g monofilament was
not felt at one site then a score of 4 was recorded even if the
patient was able to feel the 2g monofilament at the other two sites.
Section C measures motor function of ten nerves (facial, ulnar,
median, radial, posterior tibial) by voluntary muscle testing (VMT)
using the MRC grading system [12]. Normal muscle power (MRC
Grade 5) scores zero on the scale. Grade 4 scores 1 and grade 3
scores two. An MRC grade of less than three scores three on the
severity scale.
Author Summary
Leprosy is caused by a bacterium and is curable with a
combination of antibiotics known as multi-drug therapy
which patients take for six or 12 months. However, a
significant proportion of leprosy patients experience
inflammation in their skin and/or nerves which may occur
even after successful completion of multi-drug therapy.
These episodes of inflammation are called leprosy Type 1
reactions. Type 1 reactions are an important complication
of leprosy because they may result in nerve damage which
leads to disability and deformity. Type 1 reactions require
treatment with immunosuppressive agents such as corti-
costeroids. The severity of Type 1 reactions varies with
time, treatment and between individuals. We have
developed a clinical severity scale to measure the severity
of Type 1 reactions. The scale has three sections. The first
measures the involvement of the skin using the number of
affected skin lesions, the degree of inflammation of those
lesions and the presence of swelling of the hands, feet or
face. The second section is a measurement of the sensory
function of the nerves supplying the eyes, hands and feet
by assessing a patient’s ability to feel graded nylon fibres.
The third section uses a standard measure of muscle
power to assess motor function of the nerves of the face,
hands and feet. The clinical severity scale we have
developed will facilitate the study of Type 1 reactions
and enable direct comparison between different studies.
This will improve the management of this disabling
complication of leprosy.
Figure 1. Test sites on the hands (2 and 10g) and the feet (10 and 300g).
doi:10.1371/journal.pntd.0000351.g001
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scale score which ranges from 0–96, the lower the score the less
severe the reaction.
Scale testing
The assessment of the severity scale was performed at the
specialist leprosy referral centres of DBLM Hospital, Nilphamari,
Bangladesh and Oswaldo Cruz Institute, Rio de Janeiro, Brazil
between June 2006 and November 2007.
Ethical approval was granted for the external validation of the
scale and the assessment of inter-observer agreement by the Ethics
committee of the London School of Hygiene and Tropical
Medicine, the Bangladesh Medical Research Council and the
Institutional Review Board of the Oswaldo Cruz Institute.
Patients attending the centres with evidence of a Type 1
reaction or nerve function impairment of less than 6 months
duration were eligible. Eligible individuals were invited to
participate by the attending physician.
Written informed consent was obtained from individuals who
participated in the external validation of the scale and also from
those enrolled in the study of inter-observer agreement.
Individuals were examined independently by a worker who
was trained to use the scale and experienced leprologists (.20
years experience) who categorized the reaction as mild or
moderate or severe. Neither assessor (nor the patient) was aware
of the result of the others examination. All of the demographic
and clinical data were recorded on a standard form. The Ridley-
Jopling classification was used to classify the type of leprosy each
patient had [2].
Inter-observer agreement was tested at the two centres in a
subsequent stage of the study using the same eligibility criteria.
Two assessors independently used the scale to assess individuals
diagnosed as having Type 1 reactions. The scale was applied in the
same way as in the validation part of the study. The time interval
between the two assessments was kept as short as was practicable.
Four pairs of assessors were used.
The results were entered into an Access database. The data
were analysed using the Statistical Package for the Social Sciences
(SPSS version 14. SPSS Inc, Illinois, Chicago).
Statistical Methods
The item to total score correlation was examined using
Spearman rank correlation.
The internal consistency or reliability was assessed using
Cronbach’s alpha. An alpha between 0.7 and 0.9 is considered
acceptable [13]. The contribution of each item in the scale was
assessed by calculating Cronbach’s alpha for the scale if that item
were removed.
The ability of the scale to discriminate between different clinical
severity categories was determined using analysis of variance. The
threshold for accepting statistical significance was p,0.05.
Inter-observer reliability was evaluated using Intra-Class
Correlation of the total score of each examiner using a two-way
analysis of variation ( 5% level of significance) and the strength of
agreement criteria of Landis and Koch [14]. A Bland Altman plot
of the difference between pairs of observations and the mean of
those pairs was used to highlight any potential systematic
differences between raters.
Receiver Operating Characteristic (ROC) curves were used to
determine cut off points for mild, moderate and severe reactions
by calculating the sensitivity and specificity of the scale scores for
mild and moderate groups and moderate and severe groups
respectively.
Results
Expert opinion
The questionnaire sent to eight leprologists was returned by
seven. The features of Type 1 reaction that were considered
important indicators of severity were extent and degree of
inflammation of skin lesions, the presence of peripheral oedema,
nerve tenderness and nerve function impairment. These param-
eters are all part of the clinical severity scale we have developed
and thus gives our scale face validity.
Scale testing
81 individuals were recruited (56 from Bangladesh and 25 from
Brazil). 64 (79%) were male and 17 (21%) female. The clinical
features are summarised in Table 1.
Table 1. Characteristics of the participants in each stage of the study, validity and interobserver agreement.
Validity Number (%) Interobserver Agreement Number (%)
Number 81 39
Gender Male 64 (79) Male 29 (74.4)
Female 17 (21) Female 10 (25.6)
Mean Age in years (range) 39.5 (11–86) 40.9 (11–95)
Type of leprosy BT 56(69.1) BT 17 (43.6)
BB 6 (7.4) BB 3 (7.7)
BL 18 (22.2) BL 15 (38.5)
LL 4 (4.9) LL 4 (10.3)
PNL 1 (1.2) PNL 0 (0)
First episode of Type 1 reaction 52 (64.2) 19 (48.7)
Type of reaction Skin and nerves 56 (69.1) Skin and nerves 28 (71.8)
Skin only 18 (22.2) Skin only 9 (23.1)
Nerves only 7 (8.6) Nerves only 7 (5.1)
doi:10.1371/journal.pntd.0000351.t001
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+0.73. Nerve pain and nerve tenderness appeared to show no
correlation with the total score.
The internal consistency of the scale was assessed using
Cronbach’s alpha. The Cronbach’s alpha was 0.819. Removal
of the following individual items resulted in an increase in the
alpha: the degree of inflammation of skin lesions, the number of
raised inflamed lesions, nerve pain, nerve tenderness, fever,
function of right trigeminal nerve, function of the left trigeminal
nerve, motor function of the right and left radial nerves (Table 2).
This indicates that removal of one or more of these items might
improve the ability of the remaining items to measure the severity
of Type 1 reactions.
Principal component analysis (PCA) identified a general factor to
which all but nerve pain, nerve tenderness and the number of
inflamed lesions contributed accounting for 23.5% of total variance.
The important variables in the second factor accounting for 11.6%
of the total variance were those related to the eye, namely,
trigeminal nerve sensation and facial nerve motor function. The
third factor which accounted for 10.7% contrasted individuals with
skin signs and no NFI with those who only had NFI.
The severity of the Type 1 reaction was categorized as mild in
19 (23.5%), moderate in 40 (49.4%) and severe in 12 (14.8%). The
severity was not recorded in 10 cases.
The median scores for each category of reaction severity are
shown in the box plots in Fig. 2 with the inter-quartile range
(IQR). The median scores for each category were: mild=5.0
(IQR=11), moderate=10.5 (IQR=13) and severe=18.0
(IQR=29).
The differences between the mild and moderate group and the
moderate and severe groups did not reach statistical significance
(p=0.053 and 0.052 respectively). The performance of the scale
was not materially affected by excluding the seven individuals who
did not have skin involvement.
Thirty nine individuals (27 from Bangladesh and 12 from Brazil)
were recruited to the second stage of the study to assess inter-
observer agreement. The details of these patients are presented in
Table 1.
The Intra-Class Correlation coefficient based on a two-way
analysis of variance with a random effects model is 0.994. The
strength of agreement is very good [14].
A Bland and Altman plot [15] (Fig. 3) of the difference between
the scores for pairs of observers plotted against the mean of the
scores shows good agreement between observers with 95% of
differences less than two standard deviations from the mean.
The Final scale
The scale was adjusted and the analysis repeated in the light of
the data obtained (see Appendix S2).
The items nerve pain, nerve tenderness and fever were
removed. The rationale for removing these items was that nerve
pain and nerve tenderness performed least well of all the items in
the scale (in terms of Cronbach’s alpha). Fever was removed
because occurred in only four of the 120 participants in the study
as a whole.
We felt it was important to retain the cutaneous signs and
trigeminal and radial nerve function parameters as these are
important clinical features of Type 1 reactions.
The scores for the sensory testing (using SWM and cotton wool)
were reduced by 50% to make the maximum score possible for
each sensory nerve three. This is the maximum score possible for
each of the motor and cutaneous items.
These adjustments result in the final scale which consists of 21
items and has a range of 0–63. The maximum score possible for
sections A, B and C are 9, 24 and 30 respectively.
For this adjusted version of the scale Cronbach’s alpha
remained satisfactory at 0.833.
The median scores for each severity group were: mild=5.0,
moderate=7.5 and severe=15.25. The differences between the
mild and moderate groups (p=0.038) and the moderate and
severe groups (p=0.048) reached statistical significance.
The ROC curve for the final scale scores was plotted for
individuals identified as mild or moderate by the expert raters and
for those categorized as moderate or severe (Fig. 4). This facilitates
the determination of cut off scores for each category [13].
Using the ROC curves in conjunction with a consideration of
the clinical meaning of a given score we determined the following
cut off points. A mild Type 1 reaction is characterized using the
final scale by a score of 4 or less. A moderate reaction is a score of
between 4.5 and 8.5. A severe reaction is a score of 9 or more. The
area under the curve for mild and moderate categories is 0.701 for
the final scale (0.688 for the original scale). The area under the
curve for the moderate and severe categories is 0.734 for the final
Table 2. The Cronbach a for the scale when individual item
indicated is removed.
Type of
Parameter Item
Cronbach’s
Alpha if
Item
Deleted
Skin and oedema
signs
Degree of inflammation of skin .822
Number of raised and/or inflamed lesions .824
Peripheral oedema due to reaction .814
Nerve symptom Nerve pain and/or paraesthesia .826
Nerve sign Nerve tenderness (worst affected nerve
only)
.825
Systemic sign Fever (uC) .820
Sensory function
of nerve
Right trigeminal .821
Left trigeminal .821
Right ulnar .799
Left ulnar .789
Right median .795
Left median .803
Right posterior tibial .797
Left posterior tibial .800
Motor function
of nerve
Right facial .817
Left facial .816
Right ulnar .810
Left ulnar .807
Right median .809
Left median .808
Right radial .821
Left radial .821
Right lateral popliteal .809
Left lateral popliteal .816
An increase in a indicates thatremoval of the item is improving agreement of the
remaining scale items. (The overall a for the original 24 item scale was 0.819.)
doi:10.1371/journal.pntd.0000351.t002
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final scale is a fair discriminator between the severity categories
traditionally used by clinicians.
Discussion
In many branches of medicine a single test or diagnostic
criterion is either not available or insufficient to adequately
measure or describe a clinical syndrome. This has led to difficulties
in measuring the severity and prognosis of conditions. The
response by researchers has been to develop composite measure-
ment scales.
Psychologists have for many years been concerned with
accurately measuring and predicting behaviour and there is a
large literature on how to develop and test such measures [13,16].
The use of unpublished scales to measure outcome has been
shown to be a significant source of bias in psychiatry [17]. The
lack of clear descriptions of scales and familiarity with them make
clinical research difficult to interpret.
We have developed and prospectively validated a reliable 21
item severity scale to measure leprosy Type 1 reactions.
This scale requires the examiner to be proficient in recognising
the cutaneous signs of Type 1 reaction, the assessment of VMT
and the use of SWM. These skills are not widely practised in many
leprosy endemic countries and we anticipate that the main use of
this tool, at least initially, will be in the context of research and
referral settings.
We believe the scale is easy to use and requires little additional
training or equipment for workers based in referral centres. Using
a standard assessment form the additional time required to use the
scale is minimal.
Type 1 reactions are a significant cause of nerve function
impairment and this is the major concern of the physician
managing a patient with this condition. The scale we have
developed reflects the importance of NFI in the severity of Type 1
reactions.
VMT and SWM in the assessment of NFI have been shown to
be reliable [18]. Monofilaments have been shown to be
concordant with other sensory function tests [19]. These factors
undoubtedly contribute to the robustness of the current scale but
careful training and assessment of examiners is required [20].
The use of two monofilaments on the hands (2g and 10g) and
feet (10g and 300g) simplifies the system used in the INFIR Cohort
Study. However this also results in a higher sensory threshold
before an individual’s NFI impacts on their Type 1 reaction
severity scale score.
The INFIR Cohort study also used a single monofilament test
site for the purely sensory radial cutaneous and sural nerves [4].
These two nerves are not commonly tested in routine clinical
practice and are not included in the severity scale.
The radial cutaneous and sural nerves may be assessed using
various forms of quantitative sensory testing before new impair-
ment identified by monofilaments is demonstrable. Recently
published data analysing 188 individuals from the INFIR Cohort
Figure 2. Box plot of the Original Scale Scores by expert severity classification showing medians, interquartile ranges and
minimum and maximum scores.
doi:10.1371/journal.pntd.0000351.g002
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that impairment identified using monofilaments occurred in the
radial cutaneous nerve in 7% of individuals and in the sural nerve
in 6.1% [21]. However the definition of impairment in the radial
cutaneous nerve was the inability to feel monofilaments less than
10g or in the sural nerve less than 300g [4].
The lack of a gold standard measure of Type 1 reactions has
resulted in us having to compare the scale with the variable and
somewhat vague clinical categories of severity as mild, moderate or
severe. This has undoubtedly led to a degree of heterogeneity of
Type 1 reaction severity within these categories but despite this the
scale has performed well.
The final scale has a high degree of inter-observer reliability.
We were unable to test intra-observer reliability because of the
effect of treatment on the signs of reaction. It would be unethical
to withhold treatment. The assessment of intra-observer variation
is desirable but not absolutely necessary in scales with a high level
of inter-observer reliability [13]. The assessment of intra-observer
variation has not been possible in the development of valid scales
in other fields such as neurology [22].
In its present form we have found the adjusted scale to be valid
and sensitive. Neurological parameters are well represented and
reflect the importance of nerve function impairment. The addition
of weighting of the different components of the scale would add to
its complexity.
A consideration we have not addressed is the performance of
the scale in individuals who have nerve damage of greater than 6
months duration. The treatment of nerve damage present for this
length of time with corticosteroids is not associated with significant
clinical benefit compared to placebo [23]. Nerve damage greater
than six months duration should not be included in the severity
score. The issue of longstanding NFI can be problematic as
patients who are presenting for the first time may be unsure as to
the duration of the NFI and may have some acute NFI in a nerve
which already has some pre-existing permanent impairment.
Longstanding nerve damage in an individual who experiences a
Type 1 reaction would lead to a higher score than an individual
with an identical reaction but who has no pre-existing nerve
damage. The severity of the Type 1 reaction in the two individuals
is presumably the same. However it could be argued that
individuals who already have some degree of permanent nerve
damage have less neurological reserve and are thus more at risk
from even a mild reaction. This however needs to be formally
tested.
The scale is currently being used as an additional measure in a
clinical trial of methylprednisolone in Type 1 reactions. In this
cohort the performance of the scale over time and its ability to
reflect change will be assessed.
This is the first prospective validation of a severity scale for
leprosy Type 1 reactions. We believe it will prove a useful tool in
more accurately assessing Type 1 reactions particularly in clinical
trials where the ability to accurately compare the severity of Type
1 reactions in different patients is vital.
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Figure 3. A Bland Altman plot of the difference between the scores of the examiners and the mean of those scores (n=39).
doi:10.1371/journal.pntd.0000351.g003
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